Sartorius Stedim Biotech Share Price
Stocks
DIM
FR0013154002
Medical Equipment, Supplies & Distribution
OTC Markets Traded|
Real-time
Euronext Paris
15:28:58 02/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 208.80 EUR | +1.26% |
|
-1.79% | -0.67% |
| 10-01 | Sartorius Stedim Biotech : Buy rating from Goldman Sachs | ZD |
| 09-30 | Sartorius Stedim Biotech : Receives a Buy rating from Barclays | ZD |
| Market Cap | 20.06B 22.59B 18.76B 17.1B 32.19B 2,175B 32.63B 227B 87.86B 1,108B 84.81B 82.97B 3,557B | P/E 2026 * |
52.9x | P/E 2027 * | 40.9x |
|---|---|---|---|---|---|
| Enterprise Value | 22.07B 24.85B 20.64B 18.81B 35.41B 2,393B 35.9B 250B 96.67B 1,219B 93.3B 91.28B 3,914B | EV / Sales 2026 * |
7.06x | EV / Sales 2027 * | 6.29x |
| Free-Float |
28.47% | Yield 2026 * |
0.4% | Yield 2027 * | 0.49% |
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| DIM | Real-time | |
CBOE
| DIMp | Real-time | |
|
Börse Stuttgart
| 56S1 | Delayed | |
|
Boerse Muenchen
| 56S1 | Real-time | |
|
Tradegate
| 56S1 | Real-time | |
|
OTC Markets
| SDMHF | Delayed | |
|
Xetra
| 56S1 | Delayed | |
|
Deutsche Boerse AG
| 56S1 | Delayed | |
|
London S.E.
| 0NK7 | Delayed | |
|
CBOE
| 0NK7 | Real-time | |
|
Borsa Italiana
| 4DIM | End-of-day quote | |
|
Wiener Boerse
| DIM | End-of-day quote |
Last Transcript: Sartorius Stedim Biotech
| 1 day | +1.16% | ||
| 1 week | -1.79% | ||
| Current month | -1.97% | ||
| 1 month | +5.41% | ||
| 3 months | +14.55% | ||
| 6 months | +23.36% | ||
| Current year | -0.67% |
| 1 week | 204.2 |  | 221.6 |
| 1 month | 182.4 | | 221.6 |
| Current year | 150 | | 224 |
| 1 year | 150 | | 224 |
| 3 years | 139.1 | | 281 |
| 5 years | 139.1 | | 544 |
| 10 years | 50.13 | | 551 |
| Manager | Title | Age | Since |
|---|---|---|---|
René Fáber
CEO | Chief Executive Officer | 51 | 27/03/2023 |
| Chief Tech/Sci/R&D Officer | 61 | 07/09/2011 | |
Petra Müller
IRC | Investor Relations Contact | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 65 | 06/04/2015 | |
Susan Dexter
BRD | Director/Board Member | 70 | 06/04/2015 |
Lothar Kappich
BRD | Director/Board Member | 69 | 13/09/2017 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 17/12/25 | Sell | Company | 750,000 | 0.7706% | ||
| 16/02/24 | Buy | Chief Executive Officer | 1,716,739 | 1.8624% | ||
| 02/03/22 | Sell | Company | 200,442 | 0.2174% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.26% | -1.79% | +9.70% | -7.04% | 22.59B | |
| -0.09% | -5.09% | -27.72% | +0.42% | 167B | |
| +0.54% | -2.19% | -9.20% | +11.48% | 111B | |
| +0.70% | +0.79% | -25.08% | +0.24% | 105B | |
| +0.38% | +0.90% | -48.18% | -11.28% | 74.82B | |
| -2.21% | -0.96% | -1.49% | +69.73% | 59.11B | |
| -0.86% | +2.96% | +13.57% | +59.50% | 51.8B | |
| -0.85% | -3.62% | -7.54% | -31.27% | 48.5B | |
| +0.58% | +0.26% | -17.86% | +20.81% | 40.79B | |
| -0.40% | -1.27% | +28.72% | -9.55% | 32.54B | |
| Average | -0.10% | -0.59% | -8.51% | +10.30% | 71.27B | |
| Weighted average by Cap. | -0.06% | -1.02% | -15.73% | +9.24% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.13B 3.52B 2.92B 2.66B 5.02B 339B 5.09B 35.38B 13.7B 173B 13.22B 12.93B 555B | 3.47B 3.91B 3.25B 2.96B 5.57B 376B 5.65B 39.28B 15.2B 192B 14.68B 14.36B 616B |
| Net income | 377M 424M 353M 321M 605M 40.87B 613M 4.27B 1.65B 20.81B 1.59B 1.56B 66.85B | 481M 542M 450M 410M 772M 52.16B 783M 5.44B 2.11B 26.57B 2.03B 1.99B 85.33B |
| Net Debt | 2.01B 2.26B 1.88B 1.71B 3.23B 218B 3.27B 22.75B 8.81B 111B 8.5B 8.31B 356B | 1.76B 1.99B 1.65B 1.5B 2.83B 191B 2.87B 19.96B 7.72B 97.38B 7.46B 7.29B 313B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/10/26 | €208.80 | +1.26% | 31,179 |
| 01/10/26 | €206.20 | -3.10% | 89,732 |
| 30/09/26 | €212.80 | -2.03% | 159,882 |
| 29/09/26 | €217.20 | +0.28% | 109,142 |
| 28/09/26 | €216.60 | +1.98% | 90,637 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- DIM Stock
Select your edition
All financial news and data tailored to specific country editions
